Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top ...

The following is a summary of “Effectiveness and Safety of Ticagrelor Monotherapy After Short-Duration Dual Antiplatelet ...

These documents have become too technical, too inconsistent, and rely too much on expert opinion, Marco Valgimigli argues.

stroke or stent thrombosis compared to placebo – both given alongside aspirin plus a P2Y12 inhibitor – at one year. Once again, there was no significant observed increase in bleeding with ...

The findings showed that P2Y12 inhibitors were more effective than aspirin in reducing the risk of heart attacks and strokes.

(11) In patients undergoing CAS during emergent large vessel occlusion ischemic stroke treatment, it may be reasonable to administer a loading dose of intravenous or oral glycoprotein IIb/IIIa or ...

Background Cangrelor, an intravenous P2Y12-receptor inhibitor, is a reversible and short-acting antithrombotic medication non-inferior to irreversible glycoprotein IIb/IIIa inhibitors (GPIs) like ...

Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ...

Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...